1-20 of 57 Search Results for

qaly

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book Chapter
Series: Contributions to Nephrology
Volume: 185
Published: 26 May 2015
10.1159/000380976
EISBN: 978-3-318-05465-1
...-adjusted life years (QALY) and the incremental cost-effectiveness ratio (ICER). QALY were estimated using the EuroQOL-5 dimension. Reimbursement for medical fees in the national health insurance system was used as an indicator of costs. In a comparative analysis of hemodialysis and online HDF, a total...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 82
Published: 02 November 2015
10.1159/000382009
EISBN: 978-3-318-05499-6
... benefits to the patient. The most used measure of this health benefit is the quality-adjusted life year (QALY). The lower the ratio of cost per QALY gained, the more cost-effective a health intervention is said to be. Threshold values are often used in coverage decisions. Medicinal products with ratios...
Book Chapter
Series: Developments in Ophthalmology
Volume: 55
Published: 27 October 2015
10.1159/000431205
EISBN: 978-3-318-05565-8
... ]. Others reserve cost-utility analysis for those studies which measure the improvement in length of life and/or quality of life for the resources expended using dollars expended per quality-adjusted life year (QALY). The present authors agree that the term cost-utility analysis should be used to describe...
Book Chapter
Series: Advances in Oto-Rhino-Laryngology
Volume: 69
Published: 07 July 2010
10.1159/000318517
EISBN: 978-3-8055-9471-4
... disability. The main outcome of most generic HR-QoL questionnaires is one single measure called utility. It ranges between 1 (perfectly happy) and 0 (death). The change in utility owing to a specific intervention is called the utility gain and it is used to determine the quality-adjusted life-years or QALYs...
Book Chapter
Series: Developments in Ophthalmology
Volume: 60
Published: 24 April 2017
10.1159/000459694
EISBN: 978-3-318-06042-3
... can be limited by cost. Aflibercept and ranibizumab are substantially more expensive than bevacizumab. A post-hoc analysis was conducted to calculate the clinical costs, benefits, and cost effectiveness of each drug. The overall medical costs and quality-adjusted life-years (QALY) were calculated...
Book Chapter
Series: World Review of Nutrition and Dietetics
Volume: 106
Published: 12 February 2013
10.1159/000342527
EISBN: 978-3-318-02266-7
... perspective is a complex matter, ranging from the early stages of intrauterine development up to adult ages and ageing processes. Cost/benefit analyses of interventions on growth such as cost per DALYs (disability-adjusted life years) or QALYs (quality-adjusted life years) should be expanded on population...
Book Chapter
Series: Contributions to Nephrology
Volume: 185
Published: 26 May 2015
EISBN: 978-3-318-05465-1
... Journal 1991;101:1277-1286. 6. Takura T, Sawa Y: Medical economics of transplant: economic concepts for future development of organ transplantation. Transplantation 2009;44:60-68. 7. Kontodimopoulos N, Niakas D: An estimate of lifelong costs and QALYs in renal replacement therapy based on patients...
Book Chapter
Series: Advances in Oto-Rhino-Laryngology
Volume: 81
Published: 07 May 2018
10.1159/000485529
EISBN: 978-3-318-06315-8
... with a CHA for a range of reasons. There are some limited studies investigating the cost effectiveness of the VSB. These have demonstrated a range of cost per QALY of AMEI implantation. Snik et al. [ 24 ] reported a cost of EUR 18,655 per QALY for the use of the VSB in SNHL in patients with severe otitis...
Book Chapter
Book: Glaucoma
Series: ESASO Course Series
Volume: 8
Published: 30 September 2016
10.1159/000446148
EISBN: 978-3-318-05891-8
... together using the quality-adjusted life year (QALY). This is calculated by multiplying the utility value gain obtained by an intervention by the years of benefit gained. For example, if a surgical intervention such as cataract extraction results in an improved utility value from 0.5 pre-operatively to 0.8...
Book Chapter
Series: Frontiers in Diabetes
Volume: 24
Published: 17 November 2014
10.1159/000363486
EISBN: 978-3-318-02337-4
... policies or interventions in type 1 and type 2 diabetes mellitus. Three studies were performed in the UK and showed a gain in quality-adjusted life-years (QALYs) for people receiving CSII compared with MDI therapy at an increased cost. The incremental cost-effectiveness ratios for CSII compared...
Book Chapter
Series: Pediatric and Adolescent Medicine
Volume: 19
Published: 27 January 2015
10.1159/000368126
EISBN: 978-3-318-02799-0
... to comorbidity and eventually into quality-adjusted life years (QALYs). In long-term evaluations, discounting is applied in order to account for the time preference of the decision makers. Thresholds for the society's willingness to pay for a certain intervention effect have been defined in some countries...
Book Chapter
Series: Progress in Neurological Surgery
Volume: 34
Published: 28 May 2019
10.1159/000493072
EISBN: 978-3-318-06422-3
... cavernous malformation showing adverse radiation effects. Projected Cost-Benefit Analysis of Leksell Stereotactic Radiosurgery Table 2 shows a projected cost-benefit comparison. If SRS is compared to no treatment for CM the efficiency (quality-adjusted life years; QALY) increases from 25.25...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 66
Published: 22 July 2010
EISBN: 978-3-8055-9455-4
..., 2006;121-158 30. Dolan P, Shaw R, Tsuchiya A, et al: QALY maximisation and people's preferences: a methodological review of the literature. Health Econ 2005;14:197-208 ...
Book Chapter
Series: Pediatric and Adolescent Medicine
Volume: 19
Published: 27 January 2015
EISBN: 978-3-318-02799-0
... 1995;273:1093-1098. 29. Ungar WJ: Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated? Pharmacoeconomics 2011;29:641-652. 30. Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, Rice N, Sculpher M, Sowden A: Methods for assessing...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 66
Published: 22 July 2010
10.1159/000318952
EISBN: 978-3-8055-9455-4
...-effectiveness studies of preventive obesity interventions in children and adolescents PA Physical activity N nutrition SBP school-based program SBEP school-based education program PE physical education DALY disability-adjusted life year QALY quality-adjusted life...
Book Chapter
Series: Advances in Oto-Rhino-Laryngology
Volume: 81
Published: 07 May 2018
EISBN: 978-3-318-06315-8
... patients with severe external otitis. Arch Otolaryngol Head Neck Surg 2006;132:1210-1215. 25. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K: International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422...
Book
Book Cover Image
Series: Contributions to Nephrology
Volume: 185
Published online: 21 May 2015
Published in print: 26 May 2015
10.1159/isbn.978-3-318-05465-1
EISBN: 978-3-318-05465-1
Book Chapter
Series: Progress in Neurological Surgery
Volume: 33
Published: 22 January 2018
10.1159/000481105
EISBN: 978-3-318-06202-1
... cost of 22,700 EUR per quality-adjusted life year (QALY = 1 year of life × 1 utility value) for STN DBS. They concluded that this additional cost was cost effective for the benefit in QALY, given that it was below a derived cutoff of 50,000 EUR per QALY, which was in line with similar conclusions...
Book
Book Cover Image
Series: Nestlé Nutrition Institute Workshop Series: Clinical & Performance Program
Volume: 12
Published: 07 August 2009
10.1159/isbn.978-3-8055-8978-9
EISBN: 978-3-8055-8978-9
Book Chapter
Series: Developments in Ophthalmology
Volume: 60
Published: 24 April 2017
10.1159/000459699
EISBN: 978-3-318-06042-3
... in the cost burden with the 2 treatments for PDR; PRP is less expensive than ranibizumab injections. The cost of PRP as the initial treatment for PDR is lower by almost 60% than intravitreal ranibizumab 0.5 mg used over the first 2 years. Lin et al. [ 21 ] reported the quality-adjusted life year (QALY) value...